发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
INTRODUCTION:Vismodegib (Erivedge, Genentech) is a first-in-class inhibitor of the hedgehog (Hh) pathway, which is licensed for use in locally advanced basal cell carcinoma (BCC) and metastatic BCC. The National Institute for Health and Care Excellence withdrew recommendation for use of vismodegib secondary to a lack of data comparing vismodegib to standard supportive care. The purpose of this multicentre, international case series is to report outcomes of patients with locally advanced periocular BCC who have been treated with vismodegib. METHODS:The medical records of all patients treated with vismodegib were retrospectively reviewed across seven institutions in the United Kingdom, Australia, and New Zealand. RESULTS:Thirteen patients were identified. Seven (54%) patients were male. All BCCs were ill-defined, with seven (58%) having orbital involvement at presentation. Median treatment time was 7 months (range 2-36 months). Eleven out of 13 patients developed side effects, the most common being fatigue in six patients (46%). Median follow-up was 24 months (range 12-48 months). Complete response was found in 5/13 patients (38%) and a partial response in 8/13 patients (62%). Six patients had further surgery after vismodegib, with three classed as globe-sparing operations. Three patients developed recurrence (23%). Three patients (23%) ultimately underwent exenteration. DISCUSSION:This study demonstrates vismodegib to be a well-tolerated treatment which may, in some cases, facilitate globe-sparing surgery and hence avoid disfiguring operations such as exenteration. Uncertainty does remain regarding the long-term outcomes of patients treated with vismodegib.
展开更多
最新影响因子:4.456 | 期刊ISSN:0950-222X | CiteScore:1.56 |
出版周期:Monthly | 是否OA:YES | 出版年份:1987 |
自引率:7.00% | 研究方向:医学-眼科学 |
出版地区:ENGLAND |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
Eye is the official journal of the Royal College of Ophthalmologists. It aims to provide the practising ophthalmologist with information on the latest clinical and laboratory-based research. The journal publishes material on all aspects of ophthalmology including; external eye disease, oculo-plastic surgery, orbital and lacrimal disease, ocular surface and corneal disorders, paediatric ophthalmology and strabismus, glaucoma, medical and surgical retina, neuro-ophthalmology, cataract and refractive surgery, ocular oncology and ophthalmic pathology.
眼科是皇家眼科学院的官方刊物。它旨在为执业眼科医师提供最新的临床和实验室研究信息。该杂志发表了有关眼科各方面的材料,包括:外眼疾病、眼科整形手术、眼眶和泪腺疾病、眼表和角膜疾病、儿科眼科和斜视、青光眼、内科和外科视网膜、神经眼科、白内障和屈光手术、眼肿瘤和眼科。病理学。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
OPHTHALMOLOGY (眼科学) 3区 |
18/59 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
215 | 199 | 16 |
引文计数(2018)
文献(2015-2017)
1528次引用
982篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Ophthalmology
|
#40/108
点击查看排名表
|
|
2 |
大类(学科):Neuroscience
小类(学科):Sensory Systems
|
#29/39
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
15年经验沉淀,实体公司
运营
liting7111
liting7111
研究方向:眼科
审稿时间: 2个月内 接受率: 比较困难(25%命中)
liting7111
影响因子:1.992
ISSN:1976-1457
研究方向:NUTRITION & DIETETICS-
影响因子:1
ISSN:0139-3006
研究方向:农林科学-食品科技
影响因子:3.221
ISSN:1654-6628
研究方向:FOOD SCIENCE & TECHNOLOGY-NUTRITION & DIETETICS
影响因子:9.298
ISSN:1930-7381
研究方向:医学-内分泌学与代谢
影响因子:4.807
ISSN:1662-4025
研究方向:医学-内分泌学与代谢
影响因子:4.725
ISSN:2044-4052
研究方向:ENDOCRINOLOGY & METABOLISM-NUTRITION & DIETETICS
影响因子:1.417
ISSN:1575-0922
研究方向:-
影响因子:5.551
ISSN:0307-0565
研究方向:医学-内分泌学与代谢
影响因子:0.704
ISSN:0985-0562
研究方向:医学-内分泌学与代谢
发表一篇学和医学成像类SCI论文
需要多少钱?
专注医学期刊服务15年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
EYE 投稿经验
(由下方点评分析获得,3人参与,12212人阅读)